Therapeutic drug monitoring of antidepressants in haemodialysis patients

Clinical Drug Investigation

Volumn 32, Issue 8, 2012, Pages 539-545

  Unterecker, Stefan ^a   Mller, Philip ^a   Jacob, Christian ^a   Riederer, Peter ^a   Pfuhlmann, Bruno ^a  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

Author keywords

antidepressants; drug monitoring; haemodialysis; renal failure

Indexed keywords

AMITRIPTYLINE; MIRTAZAPINE; NORTRIPTYLINE;

ADULT; AGED; ARTICLE; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; COMPARATIVE STUDY; DIALYSATE; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG MONITORING; FEMALE; HEMODIALYSIS; HUMAN; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

ANTIDEPRESSIVE AGENTS; DRUG MONITORING; HUMANS; RENAL DIALYSIS;

EID: 84863592536     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.2165/11633560-000000000-00000     Document Type: Article

References (24)

1. Hiemke C, Baumann P, Bergemann N, et al. AGNP Consensus Guidelines for Therapeutic Drug Monitoring in Psychiatry: Update 2011. Pharmacopsychiatry 2011; 44: 195-235
2. Coresh J, Selvin E, Stevens LA, et al. Prevalence of chronic kidney disease in the United States. JAMA2007; 298: 2038-2047 (Pubitemid 350074801)
3. Balogun RA, Turgut F, Balogun SA, et al. Screening for depression in elderly hemodialysis patients. Nephron Clin Pract 2011; 118: C72-7
4. Chen CK, Tsai YC, Hsu HJ, et al. Depression and suicide risk in hemodialysis patients with chronic renal failure. Psychosomatics 2010; 51: 528e.
5. Kimmel PL. Depression in patients with chronic renal disease: What we know and what we need to know. J Psychosom Res 2002; 53: 951-956 (Pubitemid 35282627)
6. Kimmel PL, Cukor D, Cohen SD, et al. Depression in endstage renal disease patients: A critical review. Adv Chronic Kidney Dis 2007; 14: 328-334 (Pubitemid 47451837)
7. Martiny C, de Oliveira E, Silva AC, et al. Factors associated with risk of suicide in patients with hemodialysis. Compr Psychiatry 2011; 52: 465-468
8. Murtagh FE, Addington-Hall J, Higginson IJ. The prevalence of symptoms in end-stage renal disease: A systematic review. Adv Chronic Kidney Dis 2007; 14: 82-99 (Pubitemid 46014531)
9. Lopes AA, Albert JM, Young EW, et al. Screening for depression in hemodialysis patients: Associations with diagnosis, treatment, and outcomes in the DOPPS. Kidney Int 2004; 66: 2047-2053
10. Kim YK, Park CS, Ihm SH, et al. Relationship between the course of depression symptoms and the left ventricular mass index and left ventricular filling pressure in chronic haemodialysis patients. Nephrology 2011; 16: 180-186
11. Kimmel PL, Peterson RA, Weihs KL, et al. Multiple measurements of depression predict mortality in a longitudinal study of chronic hemodialysis outpatients. Kidney Int 2000; 57: 2093-2098 (Pubitemid 30252302)
12. Lopes AA, Bragg J, Young E, et al. Depression as a predictor of mortality and hospitalization among hemodialysis patients in the United States and Europe. Kidney Int 2002; 62: 199-207 (Pubitemid 34754063)
13. Hiemke C. Clinical utility of drug measurements and pharmacokinetics: Therapeutic drug monitoring in psychiatry. Eur J Clin Pharmacol 2008; 64: 159-166
14. Gross AS. Best practice in therapeutic drug monitoring. Br J Clin Pharmacol 2001; 52: 5-9
15. Hiemke C. Therapeutisches Drug Monitoring von Antidepressiva und Neuroleptika. Methodische Voraussetzungen. Psychopharmakotherapie 1995; 2: 21-23
16. Bengtsson F. Therapeutic drug monitoring of psychotropic drugs. TDM''nouveau''. Ther DrugMonit 2006; 26: 145-151
17. Böhler J, Donauer J, Keller F. Pharmacokinetic principles during continuous renal replacement therapy: Drugs and dosage. Kidney Int 1999; 56: s24-8
18. Cohen LM, Tessier EG, Germain MJ, et al. Update on psychotropic medication use in renal disease. Psychosomatics 2004; 45: 34-48 (Pubitemid 38082506)
19. Raymond CB, Wazny LD, Honcharik PL. Pharmacotherapeutic options for the treatment of depression in patients with chronic kidney disease. Nephrol Nurs J 2008; 35: 257-263
20. Schlotterbeck PM, Vehren T, Milenovic S, et al. No influence of dialysis on mirtazapine: A case report. Pharmacopsychiatry 2008; 41: 259-260
21. Baghdady NT, Banik S, Swartz SA, et al. Psychotropic drugs and renal failure: Translating the evidence for clinical practice. Adv Ther 2009; 26: 404-424
22. Dawling S, Lynn K, Rosser R, et al. The pharmacokinetics of nortriptyline in patients with chronic renal failure. Br J Clin Pharmacol 1981; 12: 39-45 (Pubitemid 11082287)
23. Dawling S, Lynn K, Rosser R, et al. Nortriptyline metabolism in chronic renal failure: Metabolite elimination. Clin Pharmacol Ther 1982; 32: 322-329 (Pubitemid 13097368)
24. Tasset JJ, Singh S, Pesce AJ. Evaluation of amitriptyline pharmacokinetics during peritoneal dialysis. Ther Drug Monit 1985; 7: 255-257 (Pubitemid 15228328)